Protein kinase inhibitors and use thereof for treatment of neimodegenerative diseases
WO2020076905A1
Protein kinase inhibitors
WO2020055973A1
Estrogen receptor targeting antagonists
US2020181175A1
Boronic derivatives of hydroxamates as anticancer agents
WO2018098270A1
Inhibitors of androgen receptor signaling
WO2017222921A1
2-hydroxyisophthalic acid and its derivatives: methods of making and applications
CN109415388A
It is adjusted under selective estrogen receptor (SERDS)
US2018200279A1
Inhibition of hsv-1-associated corneal neovascularization using inhibitors of cyclin-dependent kinase 9
EP3473630A1
Boron-based prodrug strategy for increased bioavailability and lower-dosage requirements for drug molecules containing at least one phenol (or aromatic hydroxyl) group
US2017044103A1
Anti-vasculature and anti-tubulin combretastatin analogs for treatment of cancer
US2015274714A1
Anti-migration and anti-invasion thiazole analogs for treatment of cellular proliferative disease
